MXPA03003407A - Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. - Google Patents

Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.

Info

Publication number
MXPA03003407A
MXPA03003407A MXPA03003407A MXPA03003407A MXPA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A MX PA03003407 A MXPA03003407 A MX PA03003407A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
antagonists
methods
treating rheumatoid
treating
Prior art date
Application number
MXPA03003407A
Other languages
English (en)
Inventor
Kendall M Mohler
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MXPA03003407A publication Critical patent/MXPA03003407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Se describe un metodo para el tratamiento de un mamifero afectado con artritis reumatoide que comprende la administracion de una forma soluble de receptor IL-17.
MXPA03003407A 2000-10-18 2001-10-18 Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. MXPA03003407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24123000P 2000-10-18 2000-10-18
PCT/US2001/049504 WO2002058717A2 (en) 2000-10-18 2001-10-18 Methods for treating rheumatoid arthritis using il-17 antagonists

Publications (1)

Publication Number Publication Date
MXPA03003407A true MXPA03003407A (es) 2004-05-04

Family

ID=22909803

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003407A MXPA03003407A (es) 2000-10-18 2001-10-18 Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.

Country Status (7)

Country Link
US (5) US6793919B2 (es)
EP (1) EP1326626B1 (es)
JP (2) JP2004517918A (es)
AU (2) AU2002246746B2 (es)
CA (1) CA2425506A1 (es)
MX (1) MXPA03003407A (es)
WO (1) WO2002058717A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20040136992A1 (en) * 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP2008532493A (ja) 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
EP1931697B1 (en) * 2005-09-28 2010-09-15 ZymoGenetics, Inc. Il-17a and il-17f antagonists and methods of using the same
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US20070197441A1 (en) * 2006-02-10 2007-08-23 Rixon Mark W Truncated il-17ra soluble receptor and methods of using in inflammation
ES2347840T3 (es) * 2006-02-10 2010-11-04 Zymogenetics, Inc. Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion.
CA2653625A1 (en) * 2006-05-31 2007-12-13 Vertex Pharmaceuticals Incorporated Controlled release formulations
CN101472611A (zh) * 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
EP2069784A4 (en) * 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
US20110008356A1 (en) * 2007-06-13 2011-01-13 Amgen, Inc. Il-17 heteromeric receptor complex
WO2009033091A1 (en) * 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
EP2216047A4 (en) 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent REGULATOR FOR SIGNALING THE TOLL LIKE RECEPTOR WITH A CATHEPSIN INHIBITOR AS AN ACTIVE SUBSTANCE
MX2010009100A (es) * 2008-02-21 2010-12-06 Amgen Inc Antagonistas de il-17ra-il-17rb y uso de los mismos.
WO2009147362A1 (en) * 2008-06-03 2009-12-10 Imperial Innovations Limited Method of rheumatoid arthritis treatment
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011044563A2 (en) * 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
MA33989B1 (fr) 2010-01-15 2013-02-01 Kirin Amgen Inc Formulation d'anticorps et régimes thérapeutiques
US20120201821A1 (en) * 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
CA3000207A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma-c-cytokine activity
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERIC NUCLEIC ACID (SNA) CONSTRUCTS WITH ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC KNOCKDOWN OF INTERLEUKIN-17 RECEPTOR MRNA
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4354282A (en) * 1981-03-12 1982-10-19 Joseph F. Monahan, Jr. Garment with score indicia and attachable score recording markers
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
WO1997004097A2 (en) 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6080557A (en) * 1996-06-10 2000-06-27 Immunex Corporation IL-1/TNF-α-activated kinase (ITAK), and methods of making and using the same
AU7408998A (en) * 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
US7005412B1 (en) * 1996-11-27 2006-02-28 Immunex Corporation Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6635443B1 (en) * 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6185745B1 (en) * 1998-04-28 2001-02-13 Fred Alger Clothing combination comprising a self-releasing bonding fastening means
PT1076703E (pt) * 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
DE19911902C1 (de) * 1999-03-17 2000-08-03 Daimler Chrysler Ag Verfahren und Vorrichtung zur variablen Einstellung der Bremskraft in einer hydraulischen Bremsanlage eines Kraftfahrzeugs
WO2000062790A2 (en) * 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20020045213A1 (en) 2000-03-16 2002-04-18 Shuqian Jing IL-17 receptor like molecules and uses thereof
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US6497870B1 (en) * 2000-05-22 2002-12-24 Hyseq, Inc. Therapeutic uses of il-1 receptor antagonist
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto

Also Published As

Publication number Publication date
US20090274703A1 (en) 2009-11-05
AU2007205808A1 (en) 2007-09-06
AU2007205808B8 (en) 2009-11-12
US20020136724A1 (en) 2002-09-26
US6793919B2 (en) 2004-09-21
EP1326626A2 (en) 2003-07-16
US20090130122A1 (en) 2009-05-21
US20100278840A1 (en) 2010-11-04
WO2002058717A2 (en) 2002-08-01
JP2004517918A (ja) 2004-06-17
AU2007205808B2 (en) 2009-10-15
EP1326626B1 (en) 2020-04-01
CA2425506A1 (en) 2002-08-01
WO2002058717A3 (en) 2003-02-27
AU2002246746B2 (en) 2007-05-31
JP2009035554A (ja) 2009-02-19
US20050013814A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
MXPA03003407A (es) Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
HUP0303766A3 (en) Ep4 receptor inhibitors to treat rheumatoid arthritis
MY141651A (en) Nep inhibitors for the treatment of female sexual dysfunction
HK1064921A1 (en) Sustained release formulations of oxymorphone
IL206829A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
GB2375860B (en) Method and system for generating a set of search terms
HUS1000008I1 (hu) Oldható CTLA4 molekulák alkalmazása reumatoid artritisz kezelésére
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
GB0115970D0 (en) Method and apparatus of metadata generation
EP1255765A4 (en) PHARMACEUTICAL COMPOSITION AND THERAPEUTIC TREATMENT OF RHEUMATIC ARTHRITIS
GB0314858D0 (en) Apparatus and method for producing ash
HK1044029A1 (en) Method of producing an active mineral liquid from granite
AU2001225664A1 (en) 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
GB0021776D0 (en) The treatment of inflammatory disorders
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima
GB0124272D0 (en) Method of delivering money
DK0831835T3 (da) Behandling af anorexia
SE9904260D0 (sv) Method and device for producing beverages
UA49490A (uk) Спосіб лікування ревматоїдного артриту
JO2086B1 (en) Pebble tester
MXPA02010115A (es) Composiciones mejoradas para el tratamiento de la disfuncion erectil masculina.
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia
SK93295A3 (en) Producing method of the mixture for unburnt bricks and rammed walling, and device for carrying out this method
UA49675A (uk) Спосіб лікування орнітозної пневмонії
UA33944A (uk) Спосіб інтраопераційної рн-метрії

Legal Events

Date Code Title Description
FG Grant or registration